Padova

• Study of Pumitamig in Combination with Chemotherapy Versus Nivolumab in Combination with Chemotherapy in Previously Untreated Advanced or Me … Recruiting
  2025-523263-37-00 10 2026-04-08 Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal
• Repurposing statins as adjuvants for cancer patients receiving therapy with immune checkpoint inhibitors: the STARK trial Recruiting
  2024-518500-47-00 4 2026-04-07 Non Small Cell Lung Cancer (NSCLC)
• A trial to learn how effective and safe datopotamab deruxtecan (Dato-DXd) is compared to docetaxel and how well Dato-DXd works in adults wit … Recruiting
  2024-520101-39-00 5 2026-04-01 TROP2 NMR-positive advanced or metastatic non-squamous non-small cell
• Donidalorsen Treatment in Children with Hereditary Angioedema Recruiting
  2025-523499-22-00 5 2026-04-01 Hereditary Angioedema (HAE)
• A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination with Atezolizumab … Recruiting
  2024-517490-24-00 4 2026-03-31 Small Cell Lung Cancer
• Pumitamig in Combination with Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Previously Untreated, Unresectable, or Met … Recruiting
  2025-523224-45-00 10 2026-03-30 Untreated, Unresectable or Metastatic Colorectal Cancer
• TRITON-PN: A Phase 3 Study to Evaluate the Efficacy and Safety of Nucresiran in Patients with Hereditary Transthyretin Amyloidosis with Poly … Recruiting
  2025-522544-40-00 5 2026-03-27 Hereditary transthyretin-mediated amyloidosis with polyneuropathy
• Phase 2a Study of Tafasitamab in Adults With Primary Autoimmune Blood Cell Disorders Recruiting
  2025-521286-27-00 10 2026-03-26 Immune-mediated thrombocytopenia, Autoimmune thrombocytopenia, Autoimm
• A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) Recruiting
  2025-522674-36-00 5 2026-03-24 Metabolic Dysfunction-Associated Steatotic Liver Disease
• Zanubritnib and anti-MAG neuropathy Recruiting
  2025-523091-23-00 4 2026-03-24 Peripheral anti-MAG neuropathy, waldenstrom macroglobulinemia, margina
• An induction study to investigate the efficacy and safety of duvakitug in participants with moderately to severely active Crohn's Disease Recruiting
  2025-521036-11-00 5 2026-03-23 Immune system disseases
• A study to test whether nerandomilast can help slow down changes in the lung in people with a family history of pulmonary fibrosis Recruiting
  2025-522383-33-00 5 2026-03-23 Interstitial lung diseases
• A Study of Evorpacept (ALX148) in Patients with Metastatic HER2-Positive Breast Cancer Recruiting
  2025-522012-16-00 4 2026-03-13 Breast Cancer
• ROMANCE Recruiting
  2025-521319-38-00 4 2026-03-11 metastatic colorectal cancer
• A trial to learn how well AZD4144 works, how safe it is, and how it moves throughout the body over time in adults with acute kidney injury c … Recruiting
  2025-522232-13-00 4 2026-03-06 Sepsis-associated acute kidney injury (AKI)
• An Open-Label Extension, Multi-Centered, Phase 2 Trial of TEV-56286 (Emrusolmin) for Multiple System Atrophy Recruiting
  2025-521642-14-00 4 2026-03-05 Multiple System Atrophy
• An induction study to investigate the efficacy and safety of duvakitug in participants with moderately to severely active Ulcerative Colitis Recruiting
  2025-521035-37-00 5 2026-03-02 Immune system diseases
• Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer (OPERA-02) Recruiting
  2025-522873-12-00 5 2026-02-24 ER+, HER2- Advanced Breast Cancer
• A trial to learn how safe Dato-DXd is and how well it works in people with NSCLC that has advanced after receiving osimertinib Recruiting
  2024-511362-37-00 5 2026-02-18 Non squamous non-small cell lung cancer (NSCLC)
• A Phase 2, Randomized, Open-Label Study Of Axatilimab Versus Best Available Therapy in Pediatric Participants With Chronic Graft Versus Host … Recruiting
  2025-521849-25-00 4 2026-02-17 Chronic Graft-Versus-Host Disease
• A clinical trial to learn about the effects of DZR123 and JSB462 given together in men with advanced prostate cancer that has stopped respon … Recruiting
  2025-521880-10-00 9 2026-02-16 Metastatic castrate resistant prostate cancer (mCRPC)
• "SAFE DISCONTINUATION OF ANTIDEPRESSANTS IN INDIVIDUALS WITH CLINICALLY REMITTED DEPRESSIVE DISORDERS" Recruiting
  2023-509377-23-00 6 2026-02-13 Patients with currently remitted depressive disorders.
• Pembrolizumab plus Lenvatinib in vulvar cancer patients: The prospective, multi-cohorts and multicentre, phase 2 MITO VULVA-01 study. Recruiting
  2023-509180-24-00 4 2026-02-12 vulvar cancer
• A Global Phase III Study of Puxitatug Samrotecan (AZD8205) Monotherapy Compared with Physician’s Choice of Chemotherapy for B7-H4-Selected E … Recruiting
  2024-518777-34-00 5 2026-02-11 B7-H4-Selected Advanced/Metastatic Endometrial Cancer.

Showing 169–192 of 769 trials